OBX Stock Forecast: Obsidian Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$12
−1.23% on the day

The median 12-month analyst price target for Obsidian Therapeutics, Inc. is $42. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$741.3M
Ticker Nerd rank
36/ 100
Median analyst target
$42
Analysts covering
5
Total return, dividends reinvested
1W
−4.5%
1M
−9.4%
From high
−65.7%
From low
+25.0%
$10
$35
Range since 29 July 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Obsidian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
36/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
80
Value
74
Quality
67
Issuance
50
Growth
50
Revisions
21
Volatility
14
Accruals
5

Momentum (80): The shares have been drifting up relative to others.

Accruals (5): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OBX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OBX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 29 July 2026Adjusted close, US dollars
$10$20$30$40Aug 26Sep 26Oct 26Nov 26OBXHigh $42Median $42Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$32
Low
$42
Median
$42
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Sept 2026Leerink PartnersInitiatesOutperform$32
9 Sept 2026William BlairInitiatesOutperform—
18 Aug 2026LifeSci CapitalInitiatesOutperform—
5 Aug 2026Piper SandlerInitiatesOverweight$42

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OBX.

Market Radar

This page is one stock. Monday covers all of them.

OBX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OBX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

OBX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Aug 26Sep 26Oct 26Nov 26OBXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OBX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−113.6%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Obsidian Therapeutics, Inc. has a market value of $741.3M and an enterprise value of $530.4M.

  • Shares outstanding: 61.6M.

  • Obsidian Therapeutics, Inc. employs 87 people.

market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

OBX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OBXObsidian Therapeutics, Inc.$741.3M36
RIGLRigel Pharmaceuticals, Inc.$741.7M84
ARDXArdelyx, Inc.$751.6M57
GLUEMonte Rosa Therapeutics, Inc.$729.9M48
SNDXSyndax Pharmaceuticals, Inc.$757.9M58
ORICOric Pharmaceuticals, Inc.$761.9M53
VSTMVerastem, Inc.$769.1M39

Take a look at OBX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Obsidian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about OBX

What is the OBX stock price forecast for 2026-2027?

The median 12-month analyst price target for Obsidian Therapeutics, Inc. is $42, with estimates ranging from $32 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OBX stock a buy right now?

Of the 5 analysts covering Obsidian Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Obsidian Therapeutics, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OBX?

As at 21 Nov 2026, Obsidian Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (80 of 100).

Will OBX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $42, and Ticker Nerd's factor model ranks Obsidian Therapeutics, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OBX stock forecast for 2030?

No analyst covering Obsidian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $42 over the next 12 months.

What does Obsidian Therapeutics, Inc. do?

Obsidian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on engineered cell and gene therapies for cancer, with an emphasis on solid tumors. The company develops tumor-infiltrating lymphocyte (TIL) therapies built on its proprietary cytoDRiVE platform, which is designed to control protein function using FDA-approved small-molecule drugs.

Company

About Obsidian Therapeutics, Inc.

Obsidian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on engineered cell and gene therapies for cancer, with an emphasis on solid tumors. The company develops tumor-infiltrating lymphocyte (TIL) therapies built on its proprietary cytoDRiVE platform, which is designed to control protein function using FDA-approved small-molecule drugs. Its lead program, OBX-115, is an investigational autologous TIL therapy incorporating membrane-bound IL15 to support T-cell activity, persistence, and antitumor response. Obsidian Therapeutics’ current pipeline centers on next-generation immuno-oncology treatments for advanced melanoma, non-small cell lung cancer, and other solid tumor indications. The company operates within the biotechnology sector, where its platform-based approach combines cell engineering, protein regulation, and clinical development to address difficult-to-treat cancers.

CEO Dr. Madan Jagasia M.D., M.S. · 87 employees · United States · https://obsidiantx.com